1 College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.

Objectives: Infantile hemangioma is a common benign vascular tumor that affects up to 10% of infants. Propranolol, a beta-blocker, has been used as a promising treatment for an infantile hemangioma, but its effectiveness remains controversial. Therefore, the aim of this study was to investigate the effect of propranolol in the treatment of infantile hemangioma in Erbil city.

Patients and Methods: This prospective interventional study was conducted between May 2021 and December 2022 in ………hospital in Erbil, Iraq. Finally, 42 children entered the study. Propranolol was given at a dose of 1 mg/kg/day and increased to 2-3 mg/kg/day within few days if tolerated. infants were treated and followed up for 3 to 6 months, and during this follow-up, they were checked for cardiac, respiratory, and hypoglycemic symptoms. Paired, independent, and chi-square tests were used in this study.

Results: The mean age of the infants 11.48 ± (5.251) months. The sexof the children showed that 14 (33.3%) of the infants were males and 28 (66.7%) were females. 6(14.3%) infants had hemangiomas in the limbs, 28 (66.7%) infants had hemangiomas in the head and neck, and 8 (19%) infants had hemangiomas in the trunk. The rate of response to treatment in the examined infants showed that in 27 (64.3%) infants, the treatment process had a good response and was successful. In 9 (21.4%) infants, there was a moderate response, and in 6 (14.3%) infants, there was a mild response.

Conclusion: Based on the findings of this study, propranolol can be used as an effective, and safe drug for the treatment of hemangioma.